Vile RG - Search Results

1

Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.

Harvey TJ, Burdon D, Steele L, Ingram N, Hall GD, Selby PJ, Vile RG, Cooper PA, Shnyder SD, Chester JD. Harvey TJ, et al. Among authors: vile rg. Gene Ther. 2010 Aug;17(8):1000-10. doi: 10.1038/gt.2010.45. Epub 2010 Apr 22. Gene Ther. 2010. PMID: 20410926 Free PMC article.

2

Gene transfer technologies for the gene therapy of cancer.

Vile R, Russell SJ. Vile R, et al. Gene Ther. 1994 Mar;1(2):88-98. Gene Ther. 1994. PMID: 7584073 Review.

3

A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.

Vile R, Miller N, Chernajovsky Y, Hart I. Vile R, et al. Gene Ther. 1994 Sep;1(5):307-16. Gene Ther. 1994. PMID: 7584096

4

Gene therapy for cancer, the course ahead.

Vile RG. Vile RG. Cancer Metastasis Rev. 1996 Sep;15(3):403-10. doi: 10.1007/BF00046350. Cancer Metastasis Rev. 1996. PMID: 9034599 Review.

5

Euro targeting in Leiden: the fourth meeting of the EWGT, University of Leiden, 14-17 November 1996.

Diaz RM, Vile R. Diaz RM, et al. Gene Ther. 1997 Jun;4(6):501-3. doi: 10.1038/sj.gt.3300445. Gene Ther. 1997. PMID: 9231064 No abstract available.

6

A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model.

Castleden SA, Chong H, Garcia-Ribas I, Melcher AA, Hutchinson G, Roberts B, Hart IR, Vile RG. Castleden SA, et al. Among authors: vile rg. Hum Gene Ther. 1997 Nov 20;8(17):2087-102. doi: 10.1089/hum.1997.8.17-2087. Hum Gene Ther. 1997. PMID: 9414257

7

Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity.

Chong H, Todryk S, Hutchinson G, Hart IR, Vile RG. Chong H, et al. Among authors: vile rg. Gene Ther. 1998 Feb;5(2):223-32. doi: 10.1038/sj.gt.3300584. Gene Ther. 1998. PMID: 9578842

8

Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer.

Diaz RM, Todryk S, Chong H, Hart IR, Sikora K, Dorudi S, Vile RG. Diaz RM, et al. Among authors: vile rg. Gene Ther. 1998 Jul;5(7):869-79. doi: 10.1038/sj.gt.3300690. Gene Ther. 1998. PMID: 9813657

9

Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors.

Melcher A, Murphy S, Vile R. Melcher A, et al. Hum Gene Ther. 1999 Jun 10;10(9):1431-42. doi: 10.1089/10430349950017770. Hum Gene Ther. 1999. PMID: 10395369

10

Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.

Kayaga J, Souberbielle BE, Sheikh N, Morrow WJ, Scott-Taylor T, Vile R, Chong H, Dalgleish AG. Kayaga J, et al. Gene Ther. 1999 Aug;6(8):1475-81. doi: 10.1038/sj.gt.3300961. Gene Ther. 1999. PMID: 10467372

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

298 results

Search Page

Filters